ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
April 06 2016 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system disorders, today announced that it will present at
the 15th Annual Needham Healthcare Conference on Tuesday, April 12,
2016, at 8:40 a.m. Eastern Time in New York City.
A live webcast of ACADIA’s presentation will be accessible on
the company’s website, www.acadia-pharm.com, under the investors
section and an archived recording will be available on the website
through April 26, 2016.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has a
pipeline of product candidates led by NUPLAZID™ (pimavanserin), for
which we have submitted a New Drug Application (NDA) for psychosis
associated with Parkinson’s disease to the FDA and which has the
potential to be the first drug approved in the United States for
this condition. The FDA has classified the NUPLAZID NDA as having
Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at
www.acadia-pharm.com to which we regularly post copies of our press
releases as well as additional information and through which
interested parties can subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, either alone or with a partner, including clinical
trials, the benefits to be derived from ACADIA’s product
candidates, in each case including NUPLAZID (pimavanserin), and the
potential for NUPLAZID to be the first drug approved in the United
States for psychosis associated with Parkinson’s disease. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and in collaborations with others,
and the fact that past results of clinical trials may not be
indicative of future trial results. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K
for the year ended December 31, 2015 as well as ACADIA’s subsequent
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160406005418/en/
ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Senior Director,
Investor Relations(858) 558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024